ReviewFrontiers in oncology2018
Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 175 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
175 citing papers in PubMed, 2 syntheses or guidelines pooled it, 302 citations in OpenAlex.
- Estimates of the global burden of HIV-attributable and all-cause AIDS-defining cancers: a population-based modeling study.Frontiers in public health · 2026Pooled it
- Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sjögren's Syndrome.Frontiers in immunology · 2020Pooled it
- New approach to determine the healthy immune variations by combining clustering methods.Scientific reports · 2021Trial
- Development and Initial Analytical Evaluation of a Multiplex PCR-Based Targeted NGS Assay for Expanded Viral Detection in Clinical Respiratory Specimens.Diagnostics (Basel, Switzerland) · 2026Article
- Association of EBV EBNA1 C-terminal variations with severity of Invasive ductal carcinoma.Molecular biology reports · 2026Article
- Epstein-Barr virus serological profiles and atypical patterns in a large tertiary-care cohort: a retrospective study of 11,503 patients.Medical microbiology and immunology · 2026Article
- Review
- Callitrichine herpesvirus 3 in the common marmoset is a model of Epstein-Barr virus infection and associated lymphoma.PLoS pathogens · 2026Article
- Seroprevalence and associated factors of Epstein-Barr virus among blood donors in Sana'a, Yemen.BMC infectious diseases · 2026Article
- Solitary thoracic Epstein-Barr virus-associated smooth muscle tumor presenting after kidney transplant: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- A System-Level Perspective on Epstein-Barr Virus Persistence: The Partial Lytic Reactivation.International journal of molecular sciences · 2026Review
- Selective effects of cyclin dependent kinase inhibitors in gammaherpesvirus reactivation from latency.bioRxiv : the preprint server for biology · 2026Article
- Epstein-Barr Virus (EBV) Hepatitis Treated With N-Acetylcysteine: Placebo Versus True Effect.Cureus · 2026Article
- Assessing Seroprevalence and Infection Dynamics of Oncogenic Gammaherpesviruses in South African Paediatric Patients Presenting with Inflammatory Conditions.International journal of molecular sciences · 2026Article
- Gut microbiota interactions with the immunomodulatory role of 25-hydroxyvitamin D in children with infectious mononucleosis.Frontiers in medicine · 2026Article
- Mechanisms of Epstein-Barr virus-associated autoimmunity: a comparative overview.Frontiers in immunology · 2026Review
- Detection of ongoing asymptomaticFrontiers in microbiology · 2026Article
- Mini-review on the therapeutic vaccines targeting chronic infectious diseases: Evaluation system of therapeutic vaccines targeting HPV and EBV-related cancers.Human vaccines & immunotherapeutics · 2025Review
- CD4 and CD8 T-cell response is dominated by IL-10-secreting cells in children with uncomplicated Plasmodium falciparum malaria.ImmunoHorizons · 2025Article
- From Viral Infection to Malignancy: The Dual Threat of EBV and COVID-19 in Cancer Development.Viruses · 2025Review
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Epstein-Barr virus (EBV) is a DNA lymphotropic herpesvirus and the causative agent of infectious mononucleosis. EBV is highly prevalent since it affects more than 90% of individuals worldwide and has been linked to several malignancies including PTLDs, which are one of the most common malignancies following transplantation. Among all the EBV genes, most of the recent investigations focused on studying the LMP-1 oncogene because of its high degree of polymorphism and association with tumorigenic activity. There are two main EBV genotypes, Type 1 and 2, distinguished by the differences in the EBNA-2 gene. Further sub genotyping can be characterized by analyzing the LMP-1 gene variation. The virus primarily transmits through oral secretions and persists as a latent infection in human B-cells. However, it can be transmitted through organ transplantations and blood transfusions. In addition, symptoms of EBV infection are not distinguishable from other viral infections, and therefore, it remains questionable whether there is a need to screen for EBV prior to blood transfusion. Although the process of leukoreduction decreases the viral copies present in the leukocytes, it does not eliminate the risk of EBV transmission through blood products. Here, we provide a review of the EBV epidemiology and the genetic variability of the oncogene LMP-1. Then, we underscore the findings of recent EBV seroprevalence and viremia studies among blood donors as a highly prevalent transfusion transmissible oncovirus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.